sr141716 has been researched along with Alloxan Diabetes in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguayo-Ortiz, R; Estrada-Soto, S; Hernández-Luis, F; Hernández-Vázquez, E; Ramírez-Espinosa, JJ | 1 |
| Estrada-Soto, S; Hernández-Luis, F; Hernández-Vázquez, E; Ramírez-Espinosa, JJ; Salgado-Barrera, S | 1 |
| Ho, TC; Makriyannis, A; Mastrodimou, N; Nikas, SP; Spyridakos, D; Thermos, K; Vemuri, K | 1 |
| Choi, CS; Han, JH; Kim, IY; Kim, JE; Kim, KW; Kim, W; Lee, EK; Lee, YJ; Park, JH; Rho, JG; Seong, JK; Shin, H; Son, DH; Song, BJ; Yoon, J; Yoon, SG | 1 |
| Cerón-Romero, L; Estrada-Soto, S; García-Jiménez, S; Hernández-Vázquez, E; Young-Peralta, S | 1 |
| Bae, SH; Chang, E; Kim, DH; Lee, DH; Park, CY; Yang, H | 1 |
| Biemer-Daub, G; Herling, AW; Miranville, A; Voss, MD | 1 |
| Bettoni, I; Colombo, A; Comelli, F; Costa, B; Fumagalli, P; Giagnoni, G | 1 |
| Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS | 1 |
| Cameron, NE; Cotter, MA; Ellington, HC; Ross, RA | 1 |
10 other study(ies) available for sr141716 and Alloxan Diabetes
| Article | Year |
|---|---|
Synthesis, hypoglycemic activity and molecular modeling studies of pyrazole-3-carbohydrazides designed by a CoMFA model.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Humans; Hydrazines; Hypoglycemic Agents; Male; Models, Molecular; Molecular Dynamics Simulation; Pyrazoles; Quantitative Structure-Activity Relationship; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Thermodynamics | 2013 |
Synthesis and molecular docking of N'-arylidene-5-(4-chlorophenyl)-1-(3,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbohydrazides as novel hypoglycemic and antioxidant dual agents.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Halogenation; Hydrazines; Hypoglycemic Agents; Male; Molecular Docking Simulation; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1 | 2016 |
Blockade of CB1 or Activation of CB2 Cannabinoid Receptors Is Differentially Efficacious in the Treatment of the Early Pathological Events in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Cannabinoids; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Streptozocin | 2022 |
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity.
Topics: Adipose Tissue; Animals; Brain; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Experimental; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Obese; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Rimonabant | 2018 |
Acute and subacute antidiabetic studies of ENP-9, a new 1,5-diarylpyrazole derivative.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Administration Schedule; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Mice, Inbred Strains; Molecular Docking Simulation; Piperidines; Protein Binding; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Toxicity Tests, Acute; Triglycerides | 2018 |
CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes.
Topics: Adenylate Kinase; Animals; Diabetes Mellitus, Experimental; Fatty Liver; Inflammation; Liver; NF-E2-Related Factor 2; Obesity; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant; Severity of Illness Index; Signal Transduction | 2018 |
Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Obesity Agents; Blood Glucose; Cell Line; Culture Media, Conditioned; Diabetes Mellitus, Experimental; Dietary Fats; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Lipopolysaccharides; Macrophages; Male; Mice; Obesity; Phosphorylation; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |
Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relationship, Drug; Hindlimb; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factors; Oxidative Stress; Pain; Pain Measurement; Physical Stimulation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sciatic Nerve; Time Factors | 2010 |
Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Male; Neurons; Peripheral Nerves; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Skin; Streptozocin; Time Factors; Tumor Necrosis Factor-alpha | 2010 |
The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Cannabinoids; Capsaicin; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hindlimb; In Vitro Techniques; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Reference Values; Rimonabant; Skin | 2002 |